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ABSTRACT In the rat, all receptor-bindable immunoglobulin A (IgA), and 1-4% of injected
asialoglycoprotein (ASG), are transported from blood to bile intact. The major fraction of the
ASG is degraded in hepatic lysosomes . The study described here was designed to elucidate
the sorting that occurs in hepatocytes subsequent to receptor binding of ligands not sharing
the same fate. We show that conjugation of protein with the Bolton and Hunter reagent can
be used as a probe for the lysosomal pathway, since 50% of the reagent is released into bile
after lysosomal degradation of internalized protein . Radiolabeling by iodine monochloride
was alternatively used to follow the direct pathways that deliver intact IgA and ASG to bile.
After intravenous injection of labeled proteins, first intact ASG and IgA, and then radioactive
catabolites from degraded protein, were released into bile . No proteolytic intermediates were
detected, and the transport of IgA or ASG directly to bile was not affected by the lysosomal
protease inhibitor leupeptin. These observations indicate that divergence of the direct biliary
transport pathways from the degradation pathway occurs at a stage preceding delivery to
lysosomes, possibly at the cell surface. Competition studies showed that all three pathways
(including the biliary transport of intact ASG) are receptor mediated, but even at supersatu-
rating doses the uptake and processing of IgA and ASG occur independently. We propose
that IgA and ASG receptors are not frequently in juxtaposition on the plasma membrane, but
that ASG, after binding to its receptor, is occasionally missorted into the biliary transport pool.
Proteins endocytosed by liver parenchymal cells can be pro-
cessed in one of three ways: they can be transported to bile,
returned to blood, or transferred intracellularly to lysosomes,
where they are degraded. Clearly, a fundamental question in
cell biology is how and where the cell separates proteins with
different ultimate destinations: at the cell surface before en-
docytosis, or in an intracellular compartment. Proteins using
different pathways in the liver have not yet been studied
together in the same experimental system. We have chosen
to investigate the quantitative direct biliary transport of poly-
meric immunoglobulin A (IgA)' (1-3) and the uptake into
the degradative pathway ofasialoglycoproteins (ASG) (4), and
we describe biochemical probes that permit the simultaneous
'Abbreviations used in this paper:
￿
ASFet, asialofetuin; ASG, asi-
aloglycoprotein(s); ASOr, asialo-orosomucoid; BH, Bolton and
Hunter (reagent); IgA, immunoglobulin A; SC, secretory component.
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examination of both pathways. The choice of these ligands is
ideal, because in the rat, short-term clearance ofboth proteins
is the exclusive responsibility ofliverhepatocytes (4-8).
Relevant aspects of these pathways previously described are
as follows: IgA binds to a high-affinity receptor specific for
polymeric immunoglobulins on the hepatocyte sinusoidal
membrane (9, 10). This receptor is identical to the secretory
component (SC) found attached to transported IgA, except
that it has an additional sequence, presumably to anchor the
binding site in the lipid bilayer (11, 12). The ligand-receptor
complex is endocytosed into 100-nm vesicles which then
migrate to the bile canaliculus (13, 14), whereupon secretory
IgA is released intact into bile, leaving the cleaved hydropho-
bic portion of the receptor in the canalicular membrane.
Transport and biliary release of the receptor is not dependent
on the presence of ligand (15) and both ligand and receptor
are univalent (16, 17), implying that bridging of receptors by
79the ligand is not required for uptake of IgA. It has been
postulated that the physiological role of this process is to
salvage IgA that has been synthesized locally at the mucosa
but that has escaped into lymph (18).
Mechanistically, the initial steps in the processing of ASG
are similar: ASG binds to a high-affinity transmembrane
receptor that recognizes terminal galactose residues, and is
endocytosed through a coated pit as a ligand-receptor com-
plex, into a small vesicle (19). Ongoing endocytosis of ASG
receptors also appears to occur in the absence of ligand (20,
21). However, unlike IgA-SC complexes, the ligand dissoci-
ates from its receptor shortly afterendocytosis, the receptor is
recycled back to the plasma membrane, and the ligand is
transferred to lysosomes for degradation (22-26). Recently,
Geuze et al. (27) have shown that ASG is separated from its
receptor in an intracellular compartment subjacent to the
plasma membrane. Differential binding and processing of
ASG depending on concentration and glycan structure sug-
gests that bridging by ligand of receptor binding sites may
play a role in the uptake and intracellular routing of receptor-
bound protein (28-32). The physiological relevance of ASG
processing is unknown, but it could play a role in clearing
senescent plasma proteins which have lost sialic acid from
their oligosaccharide chains.
In this paper, we make use of two radiolabeling methods to
monitor endocytosis and subsequent intracellular processing.
Labeling with the Bolton and Hunter (BH) reagent provides
a novel and unique approach for the study of the lysosomal
degradation pathway simultaneously with the direct biliary
transport of IgA, and has facilitated a detailed analysis of the
independence of the two processes. In addition, we found in
the course of this study that a small proportion of injected
ASG appears in bile as intact protein. This has been largely
ignored in the past, mainly because morphological techniques
do not lend themselves well to the study of minor pathways.
We include a detailed biochemical examination of this phe-
nomenon here, because we observed that biliary transport of
ASG is also receptor mediated, and this has important impli-
cations for the level of precision in the sorting process.
MATERIALS AND METHODS
Proteins:
￿
Rat monoclonal dimeric IgA was isolated from ascites fluid of
the plasmacytoma lines IR699 and IR22, kindly provided by H. Bazin ofthe
University of Louvain, Brussels, by ammonium sulfate and octanoic acid
precipitation (33). Human IgAI was isolated from myeloma sera in a similar
fashion. The polymeric fractions of all IgA preparations were recovered by
subsequent chromatography on Sepharose 6B (Pharmacia Fine Chemicals,
Uppsala, Sweden; 2.6 x 90cm). Human IgGfrom myeloma serum was purified
usingammonium sulfate and octanoic acid and chromatographedon Sephadex
G-200 (Pharmacia Fine Chemicals; 2.6 x 90 cm).
Human albumin was obtained from the Hoechst Pharmaceutical Co., Kan-
sas City, KS. Samples ofhuman orosomucoid (a,-acid glycoprotein), prepared
by the method of Hao and Wickerhauser (34), were generous contributions
from H. Schachter ofthe University of Toronto, and from the American Red
Cross Blood Services Laboratory, Bethesda. Human fetuin was purchased from
the Sigma Chemical Co., St. Louis. ASOr and ASFet were prepared by mild
acid hydrolysis (35): Solutions of the protein in water (orosomucoid: 4 mg
ml-'; fetuin: 75 mg ml-') were heated to 80°C and then made 0.1 N in H2SO4.
After 45 min, the hydrolysis was stopped by the addition oftwo equivalents of
solid Tris; the solution was cooled and then dialysed into PBS (0.15 M NaCl,
l mM potassium phosphate, pH 7.4). Chromatography on Sepharose 6B
revealed that aggregation or fragmentation of the proteins as a result of this
procedure was <5%. The remaining hydrolysable sialic acid measured by the
thiobarbituric assay (36) was <I% for orosomucoid and 1-7% for fetuin.
Inhibition experiments described in Fig. 7 were carried out using both ASFet
prepared by acid hydrolysis and ASFet prepared with neuraminidase: 400 mg
of fetuin in 5 ml of0.1 M acetate buffer, pH 5.6, was incubated at 37°C for 20
80
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h with 0.5 ml ofagarose-linked neuraminidase, purchasedfrom Sigma Chemical
Co. Treatment with solid-phase neuraminidase resulted in the release of54%
of the total hydrolysable sialic acid. These two preparations were shown to
compete in a reciprocal fashion for hepatic uptake and processing.
Radiolabeling and Preparation of Samples for Injec-
tion:
￿
Immunoglobulin and albumin preparations were treated with 25 mM
iodoacetamide for 30 min in PBS (pH 7.4) at room temperature to remove
reducingactivity. Proteins were labeled using iodine monochloride preparedin
our laboratory (37), at a final substitution ratio of less than one atom per
molecule protein. Free radioiodide was removed by exhaustive dialysis against
PBS containing 0.075% Nal, and then PBS alone. Radioactivity in preparations
of protein labeled using ICI was >98.5% precipitable in 15% trichloroacetic
acid; the specific activity was typically 10'-10'° cpm mg-L.
BH reagent wasprepared accordingto published methods (38), or purchased
from AmershamCorp., Arlington Heights, IL. On the day preceding a transport
experiment, 10-20 u1 of reagent (2 mCi/ml benzene) was dried in a small test
tube, and 0.1-0.5 mg of protein in 0.2 ml of 1 M Tris buffer, pH 8.0, was
added. Labeling proceededat 0°C for 30 min with periodic mixing. Preparations
were dialysed overnight against PBS containing 0.1% glycine and then twice
against PBS alone. Within 3 h of injection, the protein was passed over a
Sephadex G-50 column (0.5 x 12 cm) to remove any trace of free reagent, and
an aliquot was savedas astandard. The specific activitywas 10'-10, cpm mg'.
IgA or ASG labeled using the BH reagent showed <20% radioactive decom-
position upon incubation in plasma for 8 h at 38°C, or in bile or serum for 1 d
at room temperature or 8 d at 4°C, when assessed by gel filtration. For unusual
occasions where standard aliquots of stock labeled material showed >I0%
decomposition at the time when bile samples were to be analysed chromato-
graphically, the clearance and transport data were excluded from this study.
Between 104 and 106 cpm of "51- and "'I-labeled proteins were mixed in
200 kl of PBS and precounted before injection into each animal. This corre-
sponded to 0.01-100 ag, depending on the method oflabeling employed. Data
were corrected by computer for isotopic overlap and radioactive decay.
Clearance and Transport Experiments:
￿
Male Wistar rats (250-
350 g) were purchased from Charles River Canada, St. Constant, Quebec, and
maintained on a synthetic Basal Rat Diet, produced by Bioserv Inc., French-
town, NJ. Each rat wasanesthetized with sodium pentobarbital and maintained
in a supine position throughout the transport experiment. The femoral vein
was cannulated with PE-10 Intramedic polyethylene tubing (Clay-Adams,
Parsippany, NJ), and the bile duct was cannulated proximal to the pancreatic
duct with 20 cm of PE-50 tubing, extending through a mid-line abdominal
incision. Animals were allowed to recover from the operation for -1 h. The
mixture ofradiolabeled proteins was injectedthrough the femoral vein cannula,
and bile samples were collected for regular intervals (usually 10 min) until the
experiment was terminated at 4 h. The mean rate ofbile production was 13 mg
min' (range, 7-21 kg min'). Leupeptin inhibition experiments were per-
formed in rats weighing 200-250 g by injecting 5 mg of the drug (Sigma
Chemical Co.) in 300,ul PBS intravenously l h before the radioactive sample
(39). For calculations ofthe kinetics ofbiliary transport, the timeafter injection
was taken from the midpoint of the collection interval of each bile sample.
This was corrected for the time required to pass through the bile cannula, but
not for the time required for the bile to flow from the hepatocyte canalicular
face down the ductules to the cannular opening, which requires an interval on
the order ofa fewminutes. Total radioactivity in blood was calculated assuming
a blood volume of20 ml/300 g body wt.
Forexperiments in which clearance from the circulation wasalso monitored,
PE-10 tubing was brought into the abdomen through a small incision medial
to the thigh, and the left common iliac artery was cannulated just below the
aortic bifurcation. Just before the sample was injected into the femoral vein,
25 U of heparin (Sigma Chemical Co.) in 300 ul of 0.89% saline were
administered through the aortic cannula. During the course ofthe experiment,
up to 10 blood samples of -75 pl were withdrawn (each sample was collected
within 15 s). 50 kl was measured accurately from each aliquot, and combined
with 50 gal of heparinized saline. For all proteins except ASG, clearance half-
times were calculated as the time required to reach half the level of activity
observed in the blood sample taken 1 min after injection. For ASG, first
clearance half-times were extrapolated from the first sample taken at 1 min,
using the injected activity to calculate initial concentration. For clearance half-
time calculation only, an allowance was made for a nonclearable IgA fraction
(ICI-IgA: 13 ± 3% (mean ± SD); BH-IgA: 23 ± 3%), based on the fraction of
injected activity in the circulation at the end of the experiment. This fraction
was still precipitable in 15% trichloroacetic acid.
In inhibition studies, 100 mgofprotein (75 mg/ml PBS) was infused through
the femoral vein cannula during the 10 min preceding injection ofthe radio-
active sample, which was then followed by continuous infusion of a further
50-75 mg over the next 1.5 h. V,a. (the peak rate oftransport ofradiolabel to
bile) was calculated on the basis of 10-min collection intervals, and the rate at150 min was compared by computer with Vk in units of percent injected
radioactivity per gram bile. Standard errors and p values shown for %Vpmk at
150 min in Fig. 7 were calculated on the basis of the reciprocal logarithm of
the relative rate. In all cases where the observed difference between inhibition
experiments and autologous controls was significant by Student's Mest, the
difference was also significant by Wilcoxon's test at least at thep < 0.05 level.
In Vitro Binding Experiments:
￿
Human secretory component (SC),
prepared by affinity chromatography ofcolostral whey on IgM-Sepharose (40),
was coupled directly to Sepharose 4B activated with BrCN (41). Trace radio-
labeled IgA in 200 t41 of PBS containing 4 mg of bovine albumin per ml was
incubated overnight with 50 jul of SC-Sepharose at room temperature before
being washed and counted.
Analysis of Bile and Blood Samples:
￿
Radioactivity in bile and
plasma was counted and then analysed by gel filtration, typically within 48 h
of the original experiment, on Ultrogel ACA-44 (purchased from LKB,
Bromma, Sweden; see Fig. 2), or on Sephadex G-200 or Sepharose 6B (1 .6 x
90 cm at 12 ml h', PBS, 4°C; sample size <1.0 ml, fraction size 2.0 ml).
Radiolabeled protein in plasma to be used for reinjection was recovered by
making the sample 40% saturated in (NH4)2SO4 and dissolving and dialysing
the collected precipitate into PBS. Radiolabeled protein in bile to be used for
reinjection or analysis by gel electrophoresis was recovered by passing the
sample over an Ultrogel ACA-44 column equilibrated in 0.01% ammonium
acetate, pooling the included peak of radioactivity, and freeze-drying. 1-10 ng
of radiolabeled asialo-orosomucoid (ASOr) was recovered per pooled bile
sample. Slab gel electrophoresis in SDS was carried out by the method of
Laemmli (42), and autoradiograms were generated using Kodak X-omatic
enhancing screens. Molecular weight standards were generouslyprovided by R.
Allore ofthe Universityof Toronto.
RESULTS
Uptake and Processing of IgA and ASG
Asialo-orosomucoid (ASOr) and asialofetuin (ASFet) were
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radioiodinated either directly on tyrosine residues using iodine
monochloride (1C1) (37), or by conjugating primary amino
groups (mainly E-amino groups of lysine residues) with 3-(4-
hydroxy 5-["'I]iodophenyl) propionateby using its N-hydrox-
ysuccinimide ester, the BH reagent (38). ICI- or BH-ASG was
injected with ICI-IgA into rats intravenously, and the kinetics
of clearance from bloodand transport to bile were monitored.
All preparations of IgA and ASG were cleared rapidly from
the circulation (Fig. 1, Table I). 67% of injected ICI-IgA was
transported to bile within 150 min of injection. This corre-
sponded (within experimental confidence limits) to the frac-
tion of the IgA preparations able to bind to SC-Sepharose
(data not shown). The amount of radioactivity originally
associated with ICI-ASG detected in bile after intravenous
injection represented only 2-6% of the injected amount, and
peaked in bile -10 min before IgA (Fig. 1, C and E). In
contrast, -50% of the radioactivity originally associated with
BH-ASG was transported to bile, and reached a maximum
transport rate -7 min later than IgA (Fig. 1, D and F).
Fractionation of Radioactivity Recovered in Bile
Radiolabel from BH-ASG evidently was being processed
differently than radiolabel from ICFASG. It was therefore
important to investigate whether this reflected differential
processing of radioactive catabolites after ASG was degraded,
or whether the processing of ASG was itself affected by the
method of labeling. To address this issue, we analyzed bile
samples from transport experiments by gel filtration chro-
time after injection (min)
FIGURE 1
￿
Clearance from blood and transport to bile of radioactivity from labeled proteins. A and B show the
disappearance of radioactivity from blood for several representative experiments in which two aliquots of a single protein were
alternatively labeled with ["s11BH reagent or 1'1 1CI and injected together. C-Fshow the results of individual transport experiments,
in which IgA and asialoglycoprotein were labeled with alternative isotopes and injected together: C and E show the kinetics of
appearance of radioactivity in bile when ICI-IgA was injected with ICI-ASFet (C) or ICI-ASOr (E); in D and F, the respective
asialoglycoproteins were labeled with the BH reagent. % injected dose transported to bile/min is plotted against the elapsed time
at the midpoint of the collection interval for each bile sample, which has been corrected for the time required for the sample to
pass through the bile cannula. Symbols used in all figures: (0, O) rat dimeric IgA; (*, p) human IgG; (A, A) ASFet; (V, p) native
fetuin; (E, p) ASOr. Closed symbols are used to indicate results from protein labeled with ICI; open symbols denote proteins
labeled with the BH reagent.
kinetics of
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81matography (Fig. 2). The elution volume of ICI-IgA in bile
indicated that it had been transported >98% intact. However,
radioactivity recovered from BH-ASG eluted in two positions:
a small fraction appeared at an elution volume corresponding
to that of the injected material, and the bulk of the radioac-
tivity eluted near the void volume. In fact, the radioactivity
still bound to ASG in bile represented about the same per-
centage of the injected dose regardless of which method had
Clearance half-
￿
Number
The time of peak transport rate of radiolabel to bile is calculated for the
experiments shown in Fig. 3. For each experiment, this time was taken as the
midpoint of the 10-min interval when the transport rate (in % injected
radiolabel/g bile) was highest. First half-time of clearance of radiolabeled
protein from blood was measured via a cannula of the iliac artery in the
number of experiments shown at right. Uncertainty shown is mean ± SE
when n > 2, or mean ± range where n = 2.
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FIGURE 3 .
￿
Biliary transport of to-
tal radioactivity from labeled pro-
teins. The labeling reagent used
was ICI (hatched bars) or the BH
reagent (speckled bars). Top: ac-
cumulated radioactivity in bile at
150 min after injection (mean ±
SE, or mean ± range where n =
2). Samples were analyzed by gel
filtration as in Fig. 2 for the frac-
tion of radioactivity attached to
intact protein; this is indicated
within each bar by solid shading.
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to radioactivity that eluted after
70% of the column volume, rep-
resenting low molecular weight
catabolites. The scale of percent-
age transport to bile has been ex-
panded in the 0-5% range to dis-
play the amount of protein-asso-
ciated radioactivity transported to
bile from labeled ASG and control
proteins. Bottom: radiolabel re-
maining in blood at the end of the experiments (total radioactivity; the subfraction that is protein-bound is not indicated). IgA, rat dimeric
IgA from plasmacytoma line IR699; HSA, human serum albumin.
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IgA IgG ASFet Fet
been used for radiolabeling (Fig. 3). This suggested that the
protein was being processed identically in both cases, but that
subsequent to lysosomal degradation of ASG labeled using
the BH reagent, the radioactive tag (or a derivative) was being
excreted through the biliary tract.
Elution volume (fraction of column volume)
FIGURE 2
￿
Gel filtration analysis of radioactivity transported to bile
from labeled IgA and ASOr. Elution position from Ultrogel ACA-44
columns is shown as a fraction of the total column volume: (") ICI-
IgA; (N) ICI-ASOr; (O) BH-IgA; (p) BH-ASOr. Column conditions:
1 .6 x 35 cm at 20 ml h-' in 0.15 M NaCl, 20 mM Tris, pH 8.0,
0.02% NaN3 at 4°C; sample size <0.5 ml, fraction size 2.0 ml.
Time of maximal
appearance of
radiolabel in bile
min
time of radio-
label from
blood
min
of clear-
ance ex-
periments
10-
ICI-IgA 34.9 ± 1 .5 5.1 ± 0.4 6
BH-IgA 33 .2 ± 2 .5 5.0 ± 1 .4 2
ICI-IgG - >240 3
30-
BH-IgG - >240 2
ICI-ASFet 22 .6 ± 2 .4 0.8 ± 0.1 3
a
20-
BH-ASFet 41 .2 ± 3 .9 0.9 ± 0.1 2
T
>-'
~U
ICI-Fet - >240 3
t0
BH-Fet - >240 2 5 10~
ICI-ASOr 24.8 ± 2 .3 0.7 ± 0.1 2
BH-ASOr 40.4 ± 4.0 0.7 ± 0.1 3
ICI-HSA - >240 3
BH-HSA - >240 3To verify that the biliary appearance of low molecular
weight radioactive material from BH-ASG was reflective of
an event subsequent to receptor-mediated endocytosis, and
not due to spontaneous dissociation ofthe label in blood, we
then used the BH reagent to label a number of proteins that
are known not to be removed from the circulation. In the
subsequenttransport experiments (Fig. 3), injection oflabeled
IgG, native fetuin, and human albumin resulted in <6% of
the radioactivity appearing in bile; as expected, most of the
injected radioactivity was recovered in blood. When analyzed,
the activity remaining in blood was found to be at least 95%
protein bound (data not shown).
We then wanted to show that hepatocellular endocytosis of
BH-labeled protein did not by itself result in release of most
ofthe injected radioactivity into bile as low molecular weight
material. Thus, in the next experiment we tested the appear-
ance in bile of radiolabel from BH-IgA, since IgA is endocy-
tosed and transported without degradation. Radiolabel re-
covered from bile from these experiments was found by gel
filtration chromatography to be >90% protein bound, as
predicted (Fig. 2, lower graph). However, it was necessary to
explain why BH-IgA was cleared from blood and transported
to bile slightly less well than ICI-IgA (Fig. 3). Previous expe-
rience in our laboratory has indicated that the binding of
polymeric immunoglobulins to SC (the putative transport
receptor binding region) is acutely sensitive to perturbations
in immunoglobulin conformation, and we suspected that BH
labeling was functionally inactivating a small proportion of
the IgA molecules that otherwise would be able to bind to the
receptor. To test this possibility, identical samples of IgA were
concurrently labeled using [`I]BH reagent or "ICI. The
fraction of these preparations that could bind to human-SC
Sepharose was 53% and 73%, respectively. The preparations
were then injected together into rats, and radioactivity still in
blood at 4 h was recovered and reinjected into a new animal.
The reinjected BH-IgA and ICI-IgA were not cleared from the
circulation of the second animal, and only -6% of either
isotope was transported to bile. This demonstrated that IgA
remaining in the circulation in the initial experiment was
unable to bind to receptors in the liver, and thus represented
functionally inactive protein. The small percentage difference
in the clearance from blood and subsequent biliary transport
of BH-IgA and ICI-IgA is therefore an artifact of the labeling
technique; once bound by SC on the hepatocyte, either prep-
aration is transported quantitatively to bile.
We next turned our attention to the kinetics ofappearance
of the small fraction of intact ASG in bile. ["SI]BH-ASG and
"'ICI-ASG were injected together into the same animal, and
timed aliquots ofbile were analyzed individually by gel filtra-
tion (Fig. 4). This revealed that the protein-bound radioactiv-
ity transported was the same proportion of the injected dose
for both preparations, demonstrating that the transport of
intact ASG to bile was independent of the method oflabeling.
The totalradioactivity from ICI-ASG peaked at the same time
as protein-bound radioactivity from either preparation, and
established ICI-ASG as a useful direct probe for kinetic studies
on the transport of intact protein to bile. For BH-ASG, early
bile samples were relatively enriched in protein-bound radio-
activity, but low molecular weight catabolites peaked later,
reflectingthe protein processed by the degradative pathway.
It was therefore clear that BH-labeled protein behaved like
ICI-labeled protein up to the point where ligands transported
to bile intact are separated from ligands destined for lyso-
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FIGURE 4
￿
Kinetics of transport of protein-associated and unasso-
ciated radioisotope to bile after injection of labeled ASG. ['
ul]BH-
ASOr and `10-ASOr were injected together and timed samples of
bile were analyzed on Ultragel ACA-44 as in Fig. 2 for the proportion
of radiolabel associated with intact protein (radioactivity eluting at
<70% of the column volume) or present as low molecular weight
catabolites (eluting at >70% of the column volume). (p) Total
transported radioactivity from BH-ASOr; (0) total transported radio-
activity from ICI-ASOr; (X) protein-associated radioactivity from BH-
ASOr or ICI-ASOr (superimposable).
somes. To gain more direct evidence that biliary release of
low molecular weight radioactivity from BH-ASG reflected
differential handling of radioactive catabolites subsequent to
lysosomal degradation ofthe protein, we made use of leupep-
tin, a thiol protease inhibitor that affects the activity of
cathepsins (43), thus reducing lysosomal degradation of ASG
(39, 44). As shown in Fig. 5, prior administration ofleupeptin
resulted in the accumulation of radiolabel from injected ASG
in the liver, and a decrease in the release of radioactive
catabolites from BH-ASG into bile. Thus, release of these
catabolites requires lysosomal degradation of the protein. In
contrast, there was only a slight increase in the total biliary
transport ofintact IgA and ASG (not statistically significant),
showing that direct transport of proteins to bile is quantita-
tively unaffected by the modulation of lysosomal function.
Analysis of Labeled Protein Recovered from Bile
To characterize the material that was transported to bile,
we recovered the protein-bound radioactivity by gel filtration
on Ultrogel ACA-44 and then analyzed it by SDS PAGE (Fig.
6). Prolonged exposure of the autoradiograms generated no
evidence for proteolytic intermediates large enough to be
included in the column and fixed in the gel. Calibration of
the Ultrogel columns showed that insulin was just barely
excluded from the peak area pooled for SDS gel analysis; this
established a maximum size for proteolytic fragments of IgA
or ASG that could be present in bile. When ASOr transported
to bile was passed over a 1 .6 x 90 cm Sephadex G-200
column, its elution volume was identical (within 1 % of the
column volume) to a simultaneously run ASOr standard. IgA
and ASOr found in bile therefore showed no evidence of
degradation.
To demonstrate that the ASG transferred to bile was not a
particular subfraction of the preparation predestined for bili-
ary transport, we recovered intact ICI-ASOr transported to
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FIGURE 5 Effect of leupeptin on the transport of radiolabeled
material through the liver into bile . Transport through the liver of
proteins with (+) or without (-) pretreatment of the animals by
administering 5 mg of leupeptin intravenously, 1 h before injection
of the radioactive sample . Radioactivity in bile was analyzed by gel
filtration to determine the fraction still associated with intact pro-
tein ; this is shown within the bars on the top line of the figure by
solid shading. The bottom line shows total radiolabel remaining in
liver : the liver was perfused in situ through the portal vein with ice-
cold saline, and then the whole organ was removed for counting .
IgA, rat dimeric IgA from plasmacytoma line IR22 ; p, probability of
equal means for control and leupeptin experiments with the same
ligand, calculated by the two-sided Student's Mest .
bile from one experiment to use it in a subsequent study: If
theASOr recovered from bile was indeed a special subfraction
of the original preparation, then it should transport almost
completely to bile when reinjected into a second animal .
When this experiment was performed, the reinjected ASOr
was cleared from the circulation of the second animal, but
again only a small fraction (4.8%) ofthe dose was transported
to bile intact .
IgA and ASG Uptake and Processing Are Not
Cross-inhabitable
To determine whether IgA and ASG receptors are suffi-
ciently close on the plasma membrane of the hepatocyte for
cross-modulation of endocytosis to occur, we performed a
series of inhibition experiments . Labeled protein was injected
intravenously and bile was monitored for radioactivity, using
the following probes : ICI-IgA for the IgA transport pathway ;
131-1-labelled glycoprotein for the lysosomal degradation path-
way; and ICI-labeled glycoprotein for the minor (direct biliary)
pathway of ASG transport. 10-15 min before injection of
labeled material, 100mg ofone ofseveral potential competing
proteins was infused per 300 gram body weight . This dose
was selected to ensure the presence of a large excess of
inhibitor, so that even low-affinity and less accessible receptors
would be as saturated as possible . 100 mg in 10ml of plasma
is equivalent to -2 x 10-°M for ASFet and 3 x 10-5 M for
FIGURE 6
￿
SIDS gel autoradiograms of radiolabeled IgA and ASOr
recovered from bile . Samples were reduced in 2% 0-mercaptoeth-
anol and run on gels 12.5% in acrylamide . Tracks in which labeled
IgA or ASOr was run in the presence or absence of endogenous
protein from rat bile are shown, alongside protein recovered from
the bile of animals injected with BH-IgA (experiment A) or ICI-ASOr
(experiments B-D) . Indicated at the sides are the mobilities of
unlabeled IgA and ASOr, and the apparent molecular weights of
proteins in a standard marker mix, which were run on the same
gels and detected by staining with Coomassie Blue R-250 . Molec-
ular weight standards (x 10-3, in order of decreasing molecular
weight) were : myosin heavy chain, 0-galactosidase, phosphorylase
a, bovine albumin, isolated heavy chain from human IgG1, actin,
bovine pancreatic DNAse I, carbonic anhydrase, and cytochrome
c . IgAH and IgA L, heavy and light chains from rat dimeric IgA .
IgA . To maintain a high concentration, infusion of the com-
petitor was continued at -40 mg h- ' as the experiment
progressed .
In experiments where arterial blood was monitored for
uptake of labeled proteins, neither IgA nor ASG showed
significant increase in clearance half-time when the animals
were preinfused with the alternative ligand, when compared
with control infusions with bovine albumin . This indicated
that these two proteins did not compete at the level ofreceptor
binding . We then investigated whether there was any cross-
inhibition after the molecules had bound at the cell surface .
Data from bile transport experiments were analyzed in terms
of both the cumulative percent ofinjected dose transferred to
bile and the shape of the transport profile (Fig . 7) : When a
trace dose of radiolabeled IgA or ASG is processed by the
liver, the rate of transport to bile peaks rapidly and recovers
to a few percent of the peak value within a few hours of
injection . A competing protein that partially inhibited pro-
cessing could cause a decrease in the maximum transport rate
(V, k) and delay this recovery, without ultimately reducing
the size of the fraction transported . The recovery from peak
transport rate at a predefined timepoint can therefore be used
as a sensitive kinetic indicator of inhibition .
Results of this analysis (Fig. 7, right) show that prior infu-
sion of unlabeled ASFet was able to inhibit the processing ofà
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FIGURE 7
￿
Ligand inhibition experiments. Left: biliary transport of radiolabel from a trace dose of labeled ASFet, compared with
transport of ASFet in the presence of excess competing ligand and transport of the nondesialylated molecule (Fet) . Radioactivity
from ICI-labeled protein reflects direct transport ; activity from BH-labeled protein principally reflects the material processed by
the degradative pathway . The vertical bars illustrate the use of recovery from peak transport rate (Vpeak) as a kinetic indicator of
specific inhibition . Right : cumulative radiolabeled in bile, and the relative recovery from Vpeak at 150 min, calculated for inhibition
studies conducted on the three hepatocellular transport pathways : (1) The biliary transport of IgA (using ICI-IgA as probe, hatched
bars) ; (2) the lysosomal degradation pathway (using BH-labeled glycoprotein, speckled bars) ; and (3) the biliary transport of intact
ASG (using ICI-labeled glycoprotein, tinted bars) . Control experiments are compared with experiments conducted after infusion
of 100 mg of unlabeled protein . Bile from experiments on the third pathway (tinted bars) was further analyzed by gel filtration
chromatography for protein-bound radioactivity ; this fraction is shown within the bars of transported radiolabel by solid shading.
1C1-IgA (ligand), ICI-labeled rat dimeric IgA from the plasmacytoma line IR699 ; IgG and IgA (inhibitors), human monoclonal IgG
and polymeric IgA; HSA, human serum albumin ; p, probability of equal means when compared with control experiments with
the same ligand, using the one-sided Student's t-test (see Materials and Methods). Where p values are not shown, comparisons
with autologous control experiments were not significant at the p< 0.05 level by either the one-sided or two-sided test .
ASFet and ASOr, whether these proteins were labeled to
reflect lysosomal degradation ofASG (speckled bars) or the
transport of ASG intact to bile (tinted bars). This demon-
strates that both pathways are mediated by a receptor specific
for asialoglycoprotein . Inhibition ofASG processing by excess
unlabeled ASFet was accompanied by a 21- to 64-fold increase
in the circulating half-time of the labeled protein . Human
polymeric IgA was able to inhibit the biliary transport of rat
IgA dimer (hatched bars). In marked contrast, there was no
quantitative or kinetic evidence for cross-inhibition between
IgA and ASG processing, in terms of the degradation ofASG,
or the transport ofeither protein to bile .
DISCUSSION
The Bolton and Hunter Reagent Is a Probe for
Lysosomal Processing
All ofthe most frequently used methods ofprotein radioio-
dination, such as iodine monochloride, chloramine-T, and
lactoperoxidase, involve oxidation of iodide and direct sub-
stitution onto tyrosine residues . Labadie, Chapman, and
Aronson (45) have demonstrated that lysosomal degradation
ofASG in the hepatocyte leads to deiodination ofiodotyrosine
and subsequent return of the radioisotope to blood as iodide .
The BH reagent contains a phenol group presubstituted with
iodine, and conjugates to lysine residues by nucleophilic
substitution . It was developed as a more gentle and versatile
labeling method but results in the modification of the protein
structure with a larger substituent. We have shown in this
paper that in contrast to directly iodinated material, the
lysosomal degradation of BH-ASG results in the release of
half of the injected radioisotope into bile, mostly as material
of<6,000 mol wt . The exact chemical nature ofthis catabolite
is presently under investigation .
It is clear that BH labeling does not in itself affect the early
events in protein processing, and that regardless ofthe labeling
method employed most ASG is ultimately degraded in lyso-
somes: (a) BH-labeled IgA and ASG are cleared from blood
at the same rate as protein labeled on tyrosine residues ; (b)
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inhibited by excess unlabeled ASG ; (c) IgA and a small
proportion of injected ASG are transported to bile intact,
regardless of the labeling method used; and (d) leupeptin, a
lysosomal enzyme inhibitor, causes accumulation of the ra-
diolabel from ASG in the liver, and (for BH-ASG) inhibits
the release of radioactive catabolites into bile . The ability of
the liver to recover iodide from iodotyrosine but not BH-
lysine indicates a high degree ofspecificity for the microsomal
enzymes described by Labadie et al . (45). Data that we will
publish elsewhere show that hepatic uptake of BH-hemoglo-
bin also results in the release of radioactive catabolites into
bile : hence the release of catabolites apparently requires deliv-
ery to lysosomes but otherwise is not restricted to mediation
by any particular receptor . Thus, the BH reagent provides an
experimental probe for studying uptake and lysosomal pro-
cessing of proteins by the hepatocyte.
The Major Metabolic Pathways of IgA and ASG
Diverge Early
The experiments described in this paper were designed to
examine the interdependence of IgA and ASG processing, in
terms of both the receptors and the intracellular organelles
involved in ligand sorting . Separate receptors have previously
been described for the binding of these proteins to isolated
hepatocytes, but recent in vitro binding data have been inter-
preted by Stockert et al . (46) to imply that the receptor for
ASG participates in the uptake of IgA for biliary transport .
The work described here is the first to demonstrate that when
the ASG receptor is saturated there is no quantitative or
kinetic effect on the transport of IgA to bile. The role of a
separate receptor for IgA transport is therefore now conclu-
sively established .
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FIGURE 8
￿
Models for the partitioning of IgA andASG. Shownare the transport pathway of IgA from blood to bile, and the major
ASG pathway which leads to ligand degradation . (1) Common transport through lysosomes . ASOr is specifically degraded ; IgA
survives digestion and continues on to the canaliculus . (2) Endocytosis through common vesicles with subsequent prelysosomal
sorting . (3) Endocytosis of different ligands into specific vesicles. Our data exclude the first model .
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We know from other work that hepatocytes near the portal
triad can participate in metabolism of both IgA and ASG.
Individual cells must therefore sort the ligands according to
one of three models (Fig . 8) . First, both proteins may be
delivered to lysosomes through a common route, but IgA
may survive digestion and be subsequently transported to bile
(47). Second, IgA and ASG may be endocytosed together and
then sorted in a prelysosomal compartment: Material entering
the degradative pathway is delivered shortly after endocytosis
to intermediate vesicles of200-500 nm (48-52); intermediate
vesicles may also participate in the IgA pathway (53), and
thus IgA-ASG sorting could occur at this stage . Third, IgA
and ASG may be endocytosed from the plasma membrane
directly into separate compartments .
The data presented in this paper eliminate the possibility
that both proteins are delivered to lysosomes before sorting
(Fig. 8, model 1) : essentially all transportable IgA can be
recovered in bile, with no detectable proteolytic intermediates .
IgA is taken up more slowly but is excreted into bile more
rapidly than most of the radiolabel from BH-ASG, presum-
ably reflecting an additional time requirement for delivery to
and from lysosomes of ASG and its catabolites . The most
direct evidence against lysosomal involvement in the IgA
pathway is provided by the failure of leupeptin to decrease
the amount of IgA reaching bile . Leupeptin clearly affected
lysosomal function in our experiments, since it prevented
release of degradation products from BH-ASG and caused the
accumulation ofASG in the liver. The ensuing conclusion is
that lysosome-canalicular shuttling ofintact protein does not
occur .
Therefore two alternatives remain : that IgA-ASG sorting
occurs in a prelysosomal vesicle, or that the two ligands are
endocytosed separately from the plasma membrane (Fig . 8,
models 2 and 3) . Possible precedents for these models includethe following: Double-label studies using a2-macroglobulin,
insulin, epidermal growth factor, iodothyronine, or low den-
sity lipoprotein have shown that certain ligands cluster to-
gether in common endocytic pits and can subsequently share
intracellular vesicles (54-56). Intracellular sorting of endocy-
tosed protein precedes return of integral membrane compo-
nents back to the plasma membrane of the fibroblast (57).
Receptor-bound IgG in transit from the intestinal lumen to
blood, and other proteins endocytosed nonspecifically for
lysosomal degradation, are taken up by intestinal epithelial
cells into common vesicles and sorted intracellularly (58). On
the other hand, some membrane antigens such as Thy-1 are
excluded from coated pits (59). In placental epithelial cells,
IgG designated for placental transport is internalized sepa-
rately from IgG that is pinocytosed nonspecifically and de-
graded in lysosomes (60). The ASG receptor on livercells can
be induced to internalize without affecting transferrin or
insulin receptors on the cell surface (61). Thus, there appear
to be biological precedents for ligand sorting both before and
shortly following endocytosis.
The cross-inhibition studies described in this paper can
assist in the evaluation of these two alternatives for the
partitioning of IgA and ASG in the liver. If the two ligands
are endocytosed together through common coated pits, it is
reasonable to expect that the binding of one ligand would
interfere with the processing of the other. This is because (a)
IgA (320,000 mol wt) is larger than its receptor (SC, 90,000
mol wt) and probably overlaps it sterically, thereby limiting
interactions with membrane proteins directly adjacent; (b)
binding of ASG to its receptor induces receptor aggregation
(62); (c) covalent association of aggregated receptors is a
necessary requirement for ligand uptake by other cells (63),
implying that ligand-receptor aggregates undergoing endocy-
tosis through a single pit are tightly packed; (d) endocytosis
is slower and saturable at lowerligand concentration than the
binding of ASG to its receptor (64); and (e) on the basis of
the high surface density ofSC (9), we estimate that potentially
5% of the sinusoidal surface area is covered with IgA at
saturation: this couldbe sufficientto fill all coated pits partic-
ipating in the endocytosis of ASG (65). Thus, if IgA and ASG
were endocytosed into common vesicles, then saturation of
SC by IgA could limit ASG-induced aggregation of its recep-
tors or binding to receptors already clustered nearby; con-
versely, saturation of ASG receptors and the formation of
ligand-receptor aggregates could limit binding of IgA to neigh-
boring SC molecules or decrease the accessibility of SC to
endocytic pits. Cross-interference of endocytosis would be
measured as an increase in transport time to bile; inhibition
of binding would be reflected both in transport time and in
the rate of disappearance from blood.
Analysis of data from the inhibition studies revealed no
evidence for cross-inhibition ofeither uptake or processing of
IgA and ASG. Based on the arguments presented above, this
suggests that the two ligands are endocytosed separately at the
cell surface. The results are conceivably consistent with en-
docytosis of both ligands into common vesicles, but this is
possible only providing the membrane receptor density or
diffusion (not vesicle formation) is rate-limiting, and provid-
ing the fraction ofIgA and ASG receptors clustered with each
other on the membrane during endocytosis (including in
coated pits) is small. In addition, the active steps in the
intracellular processing of ASG have a lower capacity than
the endocytic step (64). Since the biliary transport of radiola-
bel from ICI-IgA or BH-ASG is not kinetically cross-inhibit-
able, the handling ofthese two ligands afterendocytosis must
remain independent throughout intracellular processing.
In summary, this study demonstrates that proteins entering
the bile transport and degradation pathways are recognized
by separate receptors and sorted before reaching lysosomes;
the data are most easily fitted assuming that the pathways
share no intracellular compartments.
The Intact Transport of ASG from Blood to Bile Is
Receptor-mediated
We have shown here that up to 4% of injected ASG is
transported from blood to bile intact. Other workers (66-68)
have described the non-receptor-mediated transfer or leakage
of proteins including ASG into bile, with molecular weight-
dependent and molecular weight-independent components.
Nonspecific pinocytosis by hepatocytes accounts for at least
part ofthis transfer, since injected horseradish peroxidase (for
which the hepatocyte has no knownreceptor) can be detected
in intracellular vesicles at about the rate expected from the
known rate of fluid uptake (69, 70). For many of these
proteins, clearance from the circulation is slow, and the ligand
has up to several hoursto reach bile via the nonspecific route.
However, ASG has a circulating half-time of <1 min, and is
transported to bile with a kinetic profile reflecting its rapid
clearance. We have presented data in this paperdemonstrating
that intact ASG reaches bile through a receptor-mediated
pathway specific for desialylated glycoprotein.
The key observation in reaching this conclusion is that
persistence of glycoprotein in the circulation is not accom-
panied by an increase in the fraction transferred to bile. We
achieved these conditions by injecting native fetuin, or by
injecting desialylated protein in the presence of excess ASFet.
If receptor recognition was not required for biliary transport
of ASG, then the increased time that the glycoprotein was
available in the circulation should have resulted in a concom-
itantincrease in size of the fraction reaching bile. In fact, just
the opposite occurred: the size of the transported fraction
decreased significantly, indicating that biliary transport of
intact ASG following injection of trace doses does indeed
require receptor recognition. A precedent for receptor-medi-
ated biliary transport of minor fractions of endocytosed pro-
tein has already been established: injected epidermal growth
factor has been recovered in bile covalently attached to its
receptor (71). We believe that a receptor-mediated minor
pathway may account for the appearance in bile of trace
amounts of other proteins primarily endocytosed for degra-
dation (72-77).
In discussing the mechanism for biliary transport of intact
ASG, it is again necessary to consider the possibility that
intact protein in bile represents material that has been trans-
located through hepatocyte lysosomes but has survived deg-
radation (Fig. 9, model 2). However, because of the absence
of proteolytic intermediates of ASG in bile, because intact
ASG appears in bile earlier than catabolites from BH-ASG,
and because leupeptin does not markedly alterthe proportion
ofinjected ASG that pursues the intact transport pathway, we
conclude that ASG in bile has bypassed lysosomes.
Two alternatives remain that do not invoke a special recep-
tor or cell type for the biliary transport of intact ASG (Fig. 9,
models 3 and 4): During the sorting of proteins that usually
occurs before or just after endocytosis by hepatocytes, ASG
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87FIGURE 9 Models for transport of ASG intact to bile . Possible
mechanisms for escape of ASG to bile (dotted arrows) are super-
imposed on a diagram of the principal specific transport pathways :
(1) Nonspecific pinocytosis or leakage through tight junctions . (2)
Specific transport through lysosomes, with a small proportion of
endocytosed ASG surviving digestion . (3) Misdirection of ASG
vesicles after IgA-ASG sorting is complete . (4) Receptor-dependent
missorting of ligands: ASG is occasionally missorted into vesicles
destined for the canaliculus; these vesicles may be (but are not
necesarily) the same as those responsible for biliary transport of
IgA. Models 3 and 4 are drawn assuming that ligand sorting occurs
at the plasma membrane ; analogous models can be drawn if ligand
sorting occurs intracellularly, in which case the missorting of ASG
could occur before or after release from its receptor. Of the models
shown, only 3 and 4 are consistent with the data presented .
may occasionally be missorted into adifferentligand-receptor
pool, such as an IgA vesicle destined for the bile canaliculus .
Alternatively, vesicles containing properly sorted ASG and
normally destined for lysosomes may occasionally be misdi-
rected and fuse with the bile canaliculus. Both ofthesemodels
imply that the biliary transport of many proteins may have
no essential physiological function, but occurs simply due to
an inherent degree of error in the ligand sorting process .
Occasional missorting may also result in the redirection of a
fraction ofinternalized proteinback to the surface from which
it was originally endocytosed (78) . Considering thecomplexity
of metabolic pathways in the hepatocyte, it is perhaps not
surprising that the fidelity of ligand partitioning is not com-
plete.
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